0L3C Stock Chart & Stats
$88.72
-$0.36(-0.42%)
At close: 4:00 PM EDT
$88.72
-$0.36(-0.42%)
Day’s Range― - ―
52-Week Range$62.29 - $92.50
Previous CloseN/A
Volume26.00
Average Volume (3M)169.00
Market Cap
$9.53B
Enterprise Value$14.94K
Total Cash (Recent Filing)$157.00M
Total Debt (Recent Filing)$3.81B
Price to Earnings (P/E)25.0
Beta0.84
Next Earnings
Nov 03, 2026EPS Estimate
1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.46
Shares Outstanding111,446,540
10 Day Avg. Volume204
30 Day Avg. Volume169
Financial Highlights & Ratios
PEG Ratio3.23
Price to Book (P/B)2.83
Price to Sales (P/S)0.70
P/FCF Ratio16.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$101.23Price Target Upside14.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)5.38
Revenue Forecast (FY)$13.87B
Bulls Say, Bears Say
Bulls Say
Recurring Technology RevenueThe technology business adds recurring, high-margin revenue alongside product distribution, deepening customer relationships and reducing reliance on individual equipment purchases. Subscriber growth and recurring fees can improve revenue visibility and support a more durable earnings mix over the next several quarters.
Market Share And Sales GrowthBroad growth across dental merchandise, international operations, and technology indicates continued customer adoption and a strong distribution position. Reported market share gains and faster growth in corporate and own brands can reinforce scale benefits and support sustained commercial momentum.
Operating Improvement ProgramA defined efficiency program with measurable targets provides a concrete path to offset cost pressure and expand operating income. Early benefits and a substantial expected run rate could improve earnings quality and strengthen the company’s ability to fund growth and investment.
Bears Say
Rising LeverageThe sharp increase in debt relative to equity reduces financial flexibility compared with earlier years. Higher leverage can constrain capital allocation, make acquisitions or repurchases less flexible, and leave the company with less balance-sheet capacity if operating conditions weaken.
Net Margin CompressionRevenue growth has not translated into comparable bottom-line profitability, showing weaker earnings conversion than in prior years. Persistent margin compression leaves less room to absorb costs or pricing pressure and makes successful execution of the efficiency program more important.
Leadership Transition RiskThe reorganization may simplify decision-making, but replacing several senior leaders while integrating supply chain and distribution functions creates execution risk. During the transition, accountability, operating coordination, and delivery of efficiency initiatives could be temporarily disrupted.
Henry Schein News
0L3C FAQ
What was Henry Schein’s price range in the past 12 months?
Henry Schein lowest share price was $62.29 and its highest was $92.50 in the past 12 months.
What is Henry Schein’s market cap?
Henry Schein’s market cap is $9.53B.
When is Henry Schein’s upcoming earnings report date?
Henry Schein’s upcoming earnings report date is Nov 03, 2026 which is in 38 days.
How were Henry Schein’s earnings last quarter?
Henry Schein released its earnings results on Aug 04, 2026. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03.
Is Henry Schein overvalued?
According to Wall Street analysts Henry Schein’s price is currently Undervalued.
Does Henry Schein pay dividends?
Henry Schein does not currently pay dividends.
What is Henry Schein’s EPS estimate?
Henry Schein’s EPS estimate is 1.36.
How many shares outstanding does Henry Schein have?
Henry Schein has 111,446,540 shares outstanding.
What happened to Henry Schein’s price movement after its last earnings report?
Henry Schein reported an EPS of $1.27 in its last earnings report, beating expectations of $1.24. Following the earnings report the stock price went up 2.822%.
Which hedge fund is a major shareholder of Henry Schein?
Currently, no hedge funds are holding shares in GB:0L3C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Henry Schein Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$101.23 (14.10% Upside)
$101.23 (14.10% Upside)
Blogger Sentiment
Bullish
GB:0L3C Sentiment 83%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Henry Schein
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
0L3C Company Deck
0L3C Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial update: solid top-line growth (6.7%), expanding margins, double-digit non-GAAP EPS growth (15.5%), strong adjusted EBITDA growth (12.7%), and raised full-year guidance. Management reinforced a clear value-creation program with specific savings targets ($125M run-rate by end-2026; $200M+ over time) and early implementation steps producing measurable benefits. Technology and recurring-revenue businesses (Dentrix Ascend / Henry Schein One) showed notable strength and strategic potential. Near-term headwinds include a small decline in U.S. dental equipment, lower point-of-care diagnostic demand, meaningful Q2 restructuring charges ($29M), and reduced remeasurement gains versus prior year, which constrain GAAP clarity and EPS flow-through. Overall, the positive metrics, guidance raise, and credible execution plan outweigh the localized challenges and one-time costs.View all GB:0L3C earnings summaries0L3C Revenue Breakdown
84.48% Global Distribution and Value-Added Services
11.71% Global Specialty Products
5.12% Global Technology
-1.31% Eliminations
0L3C Stock 12 Month Forecast
Average Price Target
$101.23
▲(14.10% Upside)